A rapid improvement after psilocybin therapy can be clinically valuable, but it does not answer how long the benefit will last. Follow-up needs to establish whether symptoms remain reduced, everyday functioning improves and further treatment becomes necessary. These outcomes are more informative than the duration of the psychedelic experience itself.
Some participants remain substantially improved months or years after treatment. The evidence does not establish a guaranteed period of remission or a standard schedule for repeat psilocybin treatment. Later improvement may also reflect continuing care and changes in the person’s circumstances.12
On this page
Response, remission and recovery are different outcomes
Response usually means a specified reduction in symptom severity, often at least 50% on a rating scale. Remission means that symptoms fall below a defined threshold. A person can meet a response criterion while still having clinically important depression, and a remission score does not by itself establish restored occupational or social functioning.
Relapse and recurrence concern the return of illness after improvement, although definitions and required periods of recovery differ between studies. These terms should be tied to explicit criteria. A brief difficult week, persistent residual symptoms and a new major depressive episode are not interchangeable events.
| Question | Useful evidence | Common interpretive error |
|---|---|---|
| Did symptoms improve? | Change from a documented baseline | Calling every improvement remission |
| Was the person well at follow-up? | Symptoms and functioning at that visit | Assuming uninterrupted wellness between visits |
| Did the initial treatment cause lasting benefit? | A suitable comparison group and intervening-treatment data | Attributing all later change to the first session |
| Would another session help? | Evidence comparing retreatment with appropriate alternatives | Assuming that recurrence establishes a need for more psilocybin |
What the one-year findings show
In a prospective follow-up of 24 adults who completed two psilocybin sessions for major depressive disorder, 75% met response criteria and 58% met remission criteria at 12 months. All 24 attended the scheduled follow-up visits. These are encouraging observations, although both original study groups ultimately received psilocybin, leaving no untreated comparison group for the long-term period.1
Eight participants, one third of the sample, started or resumed daily antidepressant treatment during that year. The finding does not invalidate their improvement. It changes its interpretation: the course of recovery cannot be described as the effect of psilocybin alone for those individuals. Additional treatment should be reported as part of the clinical outcome rather than concealed as an inconvenient complication.1
A separate 2026 randomised trial followed 35 adults after psilocybin or niacin with psychological support. Clinician-rated depression favoured psilocybin at the early assessments, but the between-group difference was no longer statistically significant at day 365. The study was small and not powered to settle long-term efficacy. The one-year result establishes neither equivalence nor a durable advantage.3
These designs answer different questions. A sustained within-person improvement is clinically relevant, while a continuing advantage over a comparison treatment addresses a different causal claim. Both should remain visible when discussing the likelihood of benefit.
Six-month comparison with escitalopram
An observational extension of a trial comparing psilocybin therapy with escitalopram followed participants for six months. Twenty-five of 30 people assigned to psilocybin and 21 of 29 assigned to escitalopram completed that assessment. Both groups remained improved, with no statistically significant between-group difference on the depression measure. Some secondary measures of functioning, connectedness and meaning favoured psilocybin.4
The extension was descriptive, with missing data and possible additional interventions after the original treatment period. Safety was not assessed during this follow-up. It therefore cannot establish that the approaches are equally effective or equally safe over six months, and favourable secondary findings should not be used to erase the uncertainty around depression outcomes.4
Interpreting a five-year follow-up
A later report from the 24-person depression cohort obtained completed follow-up from 18 participants approximately five years after treatment. It reported 67% remission in an analysis that assigned baseline scores to six non-completers. This supports the possibility of substantial long-term improvement in some participants.5
It does not demonstrate continuous remission throughout five years. Assessments separated by long intervals cannot reconstruct every intervening episode, and an uncontrolled follow-up cannot isolate the initial intervention from later care or life events. Carrying baseline scores forward is an assumption about missing outcomes, not a measurement of the six absent participants.5
It is also a later observation of the original cohort, not an independent replication. Several publications from the same participants add information about their course, but do not create several separate samples. Treatment decisions should therefore consider the number and diversity of people studied as well as the length of follow-up.
When symptoms return
The first task is reassessment. Returning symptoms may reflect recurrence of the original disorder, residual symptoms that never fully resolved, a new stressor, an adverse effect, medication withdrawal or another clinical condition. Their timing in relation to psilocybin is relevant, but does not settle the explanation.
A dramatic initial response can make recurrence particularly disappointing. It should not be framed as a failure to integrate correctly or evidence that the person did not work hard enough. Expectations of permanent transformation can add shame to an already difficult clinical situation.
NICE’s depression guidance recommends discussing relapse risk and options for continuing treatment after remission. Planning can include early warning signs, foreseeable stresses, useful psychological strategies and an agreed route back into care. These are established principles of depression management; they are not evidence for a psilocybin-specific maintenance schedule.6
Worsening mood, persistent sleep disruption or declining function warrants review. Marked agitation, psychotic symptoms or immediate risk of self-harm requires prompt clinical assessment. Medication should not be stopped or changed without an appropriate prescribing review.7
Repeat treatment remains a separate clinical question
Receiving two planned administrations in a research protocol is not the same as receiving another course after relapse. A retreatment strategy needs evidence about who should receive it, the trigger for offering it, the interval, the additional benefit and cumulative harms. Evidence for an initial course cannot simply answer all these questions.
Important comparisons include repeat psilocybin, continued psychological treatment, established pharmacotherapy and other appropriate care. A person whose symptoms returned may benefit from any of several approaches depending on diagnosis, previous response, adverse effects and preferences. The NNDC consensus identifies dosing, sustained benefit and longer-term safety among the questions requiring further research.2
The absence of an agreed maintenance schedule does not mean that no further treatment is available. It means that the choice should be guided by clinical assessment and the strength of evidence for the available options. Pursuing repeated experiences without reassessment can also delay recognition of deterioration.
Following the whole course of recovery
Follow-up should record more than a depression score. Sleep, anxiety, substance use, relationships, work and the ability to manage daily demands can move in different directions. Adverse effects, additional medicines, further psychotherapy and unsupervised psychedelic use should be recorded rather than treated as background details.
A useful record distinguishes what changed, when it changed and what else was happening. It also includes people who did not respond, declined further sessions or stopped attending. A service that hears only from satisfied returning patients cannot estimate its overall results reliably.
Durable recovery may involve sustained benefit from the initial intervention, continuing support and further treatment when needed. None of these possibilities makes the person’s progress less meaningful. The clinical aim is a manageable and improving life over time, with access to care when the course changes.
References
- Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol. 2022;36:151-158. doi:10.1177/02698811211073759.
- Hosein MM, Reid MJ, Walser S, et al. Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds. EClinicalMedicine. 2025;89:103517. doi:10.1016/j.eclinm.2025.103517.
- Yngwe H, Plavén-Sigray P, Ekman CJ, et al. Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial. JAMA Netw Open. 2026;9:e2612589. doi:10.1001/jamanetworkopen.2026.12589.
- Erritzoe D, Barba T, Greenway KT, et al. Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. EClinicalMedicine. 2024;76:102799. doi:10.1016/j.eclinm.2024.102799.
- Davis AK, DellaCrosse MA, Sepeda ND, et al. Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder. J Psychedelic Stud. 2025;9:320–329. doi:10.1556/2054.2025.00461.
- National Institute for Health and Care Excellence. Quality statement 3: Preventing relapse. Depression in adults (QS8), updated 29 June 2023; accessed 11 October 2026.
- National Institute for Health and Care Excellence. Depression in adults: treatment and management (NG222). Recommendations; accessed 11 October 2026.